Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-28
DOI
10.1038/nrd.2018.136
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype
- (2018) Georgia Minakaki et al. Autophagy
- The concept of alpha-synuclein as a prion-like protein: ten years after
- (2018) Jennifer A. Steiner et al. CELL AND TISSUE RESEARCH
- Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives
- (2018) Jin-Sung Park et al. Current Neurology and Neuroscience Reports
- Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications
- (2018) Manuela Mellone et al. JOURNAL OF NEURAL TRANSMISSION
- Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
- (2018) S. Pablo Sardi et al. MOVEMENT DISORDERS
- Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
- (2018) Anthony E. Lang et al. MOVEMENT DISORDERS
- Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide
- (2018) Friederike Zunke et al. NEURON
- mGlu 4 allosteric modulation for treating Parkinson's disease
- (2018) Delphine Charvin NEUROPHARMACOLOGY
- GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers
- (2018) Sangjune Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease
- (2018) Xian-Si Zeng et al. Frontiers in Aging Neuroscience
- Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration
- (2018) Veronica Ghiglieri et al. Frontiers in Neurology
- LRRK2 activation in idiopathic Parkinson’s disease
- (2018) Roberto Di Maio et al. Science Translational Medicine
- Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
- (2017) Andrew B. West EXPERIMENTAL NEUROLOGY
- Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification
- (2017) Wai Kin D. Ko et al. EXPERIMENTAL NEUROLOGY
- Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
- (2017) Ramón Cacabelos INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery, Structure–Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4
- (2017) Delphine Charvin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Non-human primate models of PD to test novel therapies
- (2017) Marc Morissette et al. JOURNAL OF NEURAL TRANSMISSION
- Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease
- (2017) Karamjeet Kaur et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Therapies targeting DNA and RNA in Huntington's disease
- (2017) Edward J Wild et al. LANCET NEUROLOGY
- Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study
- (2017) Anette Schrag et al. LANCET NEUROLOGY
- Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
- (2017) Tim E. Moors et al. Molecular Neurodegeneration
- Targeting α-Synuclein as a therapy for Parkinson's disease: The battle begins
- (2017) C. Warren Olanow et al. MOVEMENT DISORDERS
- Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
- (2017) J.A. Obeso et al. MOVEMENT DISORDERS
- The two-century journey of Parkinson disease research
- (2017) Serge Przedborski NATURE REVIEWS NEUROSCIENCE
- Inhibitory Basal Ganglia Inputs Induce Excitatory Motor Signals in the Thalamus
- (2017) Jeongjin Kim et al. NEURON
- Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research
- (2017) Nadhir Litim et al. NEUROPHARMACOLOGY
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies
- (2017) Mathieu Bourdenx et al. PROGRESS IN NEUROBIOLOGY
- Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease
- (2017) Laurie K. Mischley et al. Journal of Parkinsons Disease
- Is Exenatide a Treatment for Parkinson’s Disease?
- (2017) Dilan Athauda et al. Journal of Parkinsons Disease
- Glucocerebrosidase Mutations in Parkinson Disease
- (2017) Grace O’Regan et al. Journal of Parkinsons Disease
- The MPTP Story
- (2017) J. William Langston Journal of Parkinsons Disease
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)
- (2017) Rajesh Pahwa et al. JAMA Neurology
- The Endoplasmic Reticulum Unfolded Protein Response in Neurodegenerative Disorders and Its Potential Therapeutic Significance
- (2017) Paolo Remondelli et al. Frontiers in Molecular Neuroscience
- The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease
- (2017) Erica L. Gorenberg et al. Frontiers in Neuroscience
- Mitophagy in Parkinson’s Disease: Pathogenic and Therapeutic Implications
- (2017) Fei Gao et al. Frontiers in Neurology
- Parkinson disease
- (2017) Werner Poewe et al. Nature Reviews Disease Primers
- Levodopa in Parkinson’s Disease: Current Status and Future Developments
- (2017) Nicola Tambasco et al. Current Neuropharmacology
- Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson’s disease
- (2017) Caroline J. Zeiss et al. PLoS One
- Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial
- (2017) Agnieszka Ciesielska et al. PLoS One
- Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review
- (2016) A. D. Andersen et al. ACTA NEUROLOGICA SCANDINAVICA
- Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice
- (2016) Anna Migdalska-Richards et al. ANNALS OF NEUROLOGY
- A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease
- (2016) David J. M. McGhee et al. BMC Neurology
- Ade novocompound targeting α-synuclein improves deficits in models of Parkinson’s disease
- (2016) Wolfgang Wrasidlo et al. BRAIN
- New concepts in the pathogenesis and presentation of Parkinsons disease
- (2016) A. Sauerbier et al. CLINICAL MEDICINE
- Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension
- (2016) Robert A. Hauser et al. CLINICAL NEUROPHARMACOLOGY
- Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors
- (2016) Stephen M. Stahl CNS SPECTRUMS
- The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
- (2016) Dilan Athauda et al. DRUG DISCOVERY TODAY
- Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
- (2016) Dhanya Vijayakumar et al. DRUGS
- The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study
- (2016) K. M. Prakash et al. EUROPEAN JOURNAL OF NEUROLOGY
- The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study
- (2016) R. Erro et al. EUROPEAN JOURNAL OF NEUROLOGY
- The relationship between glucocerebrosidase mutations and Parkinson disease
- (2016) Anna Migdalska-Richards et al. JOURNAL OF NEUROCHEMISTRY
- Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
- (2016) Abdel A. Belaidi et al. JOURNAL OF NEUROCHEMISTRY
- Mitochondrial dysfunction in Parkinson's disease
- (2016) Anindita Bose et al. JOURNAL OF NEUROCHEMISTRY
- Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication
- (2016) Seongyeol Park et al. JOURNAL OF NUCLEAR MEDICINE
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
- (2016) Richard S Finkel et al. LANCET
- Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson’s Disease
- (2016) Junjun Zhao et al. MOLECULAR NEUROBIOLOGY
- CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
- (2016) John Marshall et al. MOLECULAR THERAPY
- Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment
- (2016) Anthony H.V. Schapira et al. MOVEMENT DISORDERS
- A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
- (2016) François Tison et al. MOVEMENT DISORDERS
- Oscillatory activity in the basal ganglia and deep brain stimulation
- (2016) Jorge Guridi et al. MOVEMENT DISORDERS
- First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers
- (2016) Dale B. Schenk et al. MOVEMENT DISORDERS
- Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
- (2016) Patrick P. Michel et al. NEURON
- An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models
- (2016) Wai Kin D. Ko et al. NEUROPHARMACOLOGY
- Challenges in detecting disease modification in Parkinson's disease clinical trials
- (2016) Dilan Athauda et al. PARKINSONISM & RELATED DISORDERS
- Insulin resistance and Parkinson’s disease: A new target for disease modification?
- (2016) D. Athauda et al. PROGRESS IN NEUROBIOLOGY
- Alpha-synuclein-based models of Parkinson's disease
- (2016) B. Dehay et al. REVUE NEUROLOGIQUE
- Optimizing Transgene Configuration and Protein Fusions to Maximize Dopamine Production for the Gene Therapy of Parkinson's Disease
- (2016) Hannah J. Stewart et al. Human Gene Therapy Clinical Development
- Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque
- (2016) James B. Koprich et al. PLoS One
- Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial
- (2015) C. Warren Olanow et al. ANNALS OF NEUROLOGY
- Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
- (2015) Per Svenningsson et al. BRAIN
- A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease
- (2015) Tomoyoshi Kondo et al. CLINICAL NEUROPHARMACOLOGY
- Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease
- (2015) Marianne Amalric CURRENT OPINION IN PHARMACOLOGY
- Parkinson’s disease: a review of non-motor symptoms
- (2015) Abdul Qayyum Rana et al. Expert Review of Neurotherapeutics
- Parkinson's disease
- (2015) Lorraine V Kalia et al. LANCET
- Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
- (2015) LANCET NEUROLOGY
- Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity
- (2015) Giovanna Paolone et al. MOVEMENT DISORDERS
- Advances in clinical trials for movement disorders
- (2015) Karl Kieburtz et al. MOVEMENT DISORDERS
- Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)
- (2015) Rajesh Pahwa et al. MOVEMENT DISORDERS
- Balancing the basal ganglia circuitry: A possible new role for dopamine D2 receptors in health and disease
- (2015) Maxime Cazorla et al. MOVEMENT DISORDERS
- Proteostasis and aging
- (2015) Susmita Kaushik et al. NATURE MEDICINE
- Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells
- (2015) Giulia Ambrosi et al. NEUROBIOLOGY OF DISEASE
- Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
- (2015) Matthieu F. Bastide et al. PROGRESS IN NEUROBIOLOGY
- Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
- (2015) Reina N. Fuji et al. Science Translational Medicine
- Peripheral Biomarkers of Parkinson’s Disease Progression and Pioglitazone Effects
- (2015) David K. Simon et al. Journal of Parkinsons Disease
- Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
- (2015) Iciar Aviles-Olmos et al. Journal of Parkinsons Disease
- The Synaptic Function of α-Synuclein
- (2015) Jacqueline Burré Journal of Parkinsons Disease
- Parkinson’s disease: a review of non-motor symptoms
- (2015) Abdul Qayyum Rana et al. Expert Review of Neurotherapeutics
- Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease
- (2015) Robert A. Hauser et al. JAMA Neurology
- Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression
- (2015) Mathieu Bourdenx et al. Acta Neuropathologica Communications
- Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials
- (2014) Markus Mandler et al. ACTA NEUROPATHOLOGICA
- Prioritized research recommendations from the National Institute of Neurological Disorders and StrokeParkinson'sDisease 2014 conference
- (2014) Beth-Anne Sieber et al. ANNALS OF NEUROLOGY
- Novel levodopa formulations in the treatment of Parkinson's disease
- (2014) Manuela Pilleri et al. Expert Review of Neurotherapeutics
- Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
- (2014) D. Games et al. JOURNAL OF NEUROSCIENCE
- Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
- (2014) Stéphane Palfi et al. LANCET
- Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
- (2014) Robert A Hauser et al. LANCET NEUROLOGY
- The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model
- (2014) Erwan Bezard et al. MOVEMENT DISORDERS
- Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
- (2014) Mike A Nalls et al. NATURE GENETICS
- Functional connectivity in the basal ganglia network differentiates PD patients from controls
- (2014) K. Szewczyk-Krolikowski et al. NEUROLOGY
- Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias
- (2014) Olivier Rascol et al. PARKINSONISM & RELATED DISORDERS
- Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs
- (2014) Thomas J. Moore et al. JAMA Internal Medicine
- A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
- (2014) et al. JAMA Neurology
- Emerging Candidate Biomarkers for Parkinson’s Disease: a Review
- (2014) Enrico Saracch Aging and Disease
- Convergence of dopamine and glutamate signaling onto striatal ERK activation in response to drugs of abuse
- (2014) Emma Cahill et al. Frontiers in Pharmacology
- Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates
- (2014) Nicolas Morin et al. Frontiers in Neurology
- Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of nonhuman primate
- (2014) Waldy San Sebastian et al. Molecular Therapy-Methods & Clinical Development
- Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease
- (2013) Jens Wagner et al. ACTA NEUROPATHOLOGICA
- Glucocerebrosidase mutations and the pathogenesis of Parkinson disease
- (2013) Michelle S. Beavan et al. ANNALS OF MEDICINE
- Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
- (2013) David Devos et al. ANTIOXIDANTS & REDOX SIGNALING
- Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson’s disease and Parkinson’s disease psychosis
- (2013) David Hubbard et al. BEHAVIOURAL PHARMACOLOGY
- Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease
- (2013) Susan H. Fox DRUGS
- Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators
- (2013) Orly Weinreb et al. FREE RADICAL BIOLOGY AND MEDICINE
- Accumulation of the parkin substrate, FAF1, plays a key role in the dopaminergic neurodegeneration
- (2013) Jee-Won Sul et al. HUMAN MOLECULAR GENETICS
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
- (2013) Jeffrey Cummings et al. LANCET
- Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy
- (2013) Raymond T Bartus et al. MOLECULAR THERAPY
- Concurrent activation of striatal direct and indirect pathways during action initiation
- (2013) Guohong Cui et al. NATURE
- Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease
- (2013) Laura Dunn et al. NEUROBIOLOGY OF AGING
- Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
- (2013) F. Ory-Magne et al. NEUROLOGY
- Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys
- (2013) Laurent Grégoire et al. PARKINSONISM & RELATED DISORDERS
- Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
- (2013) Daniel Ness et al. PLoS One
- Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies
- (2013) S. Pablo Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease
- (2013) Eleftheria K. Pissadaki et al. Frontiers in Computational Neuroscience
- Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
- (2012) Susan Duty CNS DRUGS
- Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
- (2012) Gabriele Mittermeyer et al. HUMAN GENE THERAPY
- NADPH Oxidase 1 Mediates -Synucleinopathy in Parkinson's Disease
- (2012) A. C. Cristovao et al. JOURNAL OF NEUROSCIENCE
- Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial
- (2012) Caroline Moreau et al. LANCET NEUROLOGY
- Alpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship
- (2012) Maria Xilouri et al. MOLECULAR NEUROBIOLOGY
- Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies
- (2012) Erwan Bezard et al. MOVEMENT DISORDERS
- Living on the edge with too many mouths to feed: Why dopamine neurons die
- (2012) J. Paul Bolam et al. MOVEMENT DISORDERS
- The many faces of α-synuclein: from structure and toxicity to therapeutic target
- (2012) Hilal A. Lashuel et al. NATURE REVIEWS NEUROSCIENCE
- Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism
- (2012) David N. Hauser et al. NEUROBIOLOGY OF DISEASE
- -Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
- (2012) M. Decressac et al. Science Translational Medicine
- Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinsonʼs disease
- (2011) Krista McFarland et al. BEHAVIOURAL PHARMACOLOGY
- The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
- (2011) Christine R Swanson et al. Journal of Neuroinflammation
- Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine Phosphorylation: Implications for Parkinson's Disease
- (2011) S. Z. Imam et al. JOURNAL OF NEUROSCIENCE
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
- (2011) Robert A Hauser et al. LANCET NEUROLOGY
- AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials
- (2011) Daniela Berg et al. MOVEMENT DISORDERS
- The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease
- (2011) D.J. Surmeier et al. NEUROSCIENCE
- The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys
- (2011) Laurent Grégoire et al. PARKINSONISM & RELATED DISORDERS
- Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
- (2011) Eliezer Masliah et al. PLoS One
- Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders
- (2010) Robert A. Hodgson et al. EXPERIMENTAL NEUROLOGY
- Are synucleinopathies prion-like disorders?
- (2010) Elodie Angot et al. LANCET NEUROLOGY
- Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry
- (2010) Alexxai V. Kravitz et al. NATURE
- Prion-like transmission of protein aggregates in neurodegenerative diseases
- (2010) Patrik Brundin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease
- (2010) K. A. Chung et al. NEUROLOGY
- Metabotropic glutamate receptors: From the workbench to the bedside
- (2010) F. Nicoletti et al. NEUROPHARMACOLOGY
- α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra
- (2010) Alison L. McCormack et al. PLoS One
- Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function
- (2010) H. S. Ko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors
- (2010) H. S. Bateup et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mitochondrial dysfunction in Parkinson's disease
- (2009) Konstanze F. Winklhofer et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Combination therapy with Coenzyme Q10and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases
- (2009) Lichuan Yang et al. JOURNAL OF NEUROCHEMISTRY
- Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV -Synucleinopathy
- (2009) C. Y. Chung et al. JOURNAL OF NEUROSCIENCE
- Axonal Transport Defects in Neurodegenerative Diseases
- (2009) G. A. Morfini et al. JOURNAL OF NEUROSCIENCE
- Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria
- (2009) Dennis W Dickson et al. LANCET NEUROLOGY
- Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
- (2009) Robert A. Hauser et al. MOVEMENT DISORDERS
- D2R striatopallidal neurons inhibit both locomotor and drug reward processes
- (2009) Pierre F Durieux et al. NATURE NEUROSCIENCE
- Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF
- (2009) M.E. Emborg et al. NEUROBIOLOGY OF DISEASE
- Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
- (2009) Herbert Y Meltzer et al. NEUROPSYCHOPHARMACOLOGY
- Dopamine Gene Therapy for Parkinson's Disease in a Nonhuman Primate Without Associated Dyskinesia
- (2009) B. Jarraya et al. Science Translational Medicine
- Treatment of imbalance with varenicline (Chantix®): report of a patient with fragile X tremor/ataxia syndrome
- (2008) T. A. Zesiewicz et al. ACTA NEUROLOGICA SCANDINAVICA
- Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now